Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pseudolymphoma | 2 | 2018 | 11 | 1.50 | Why? |
| Sweat Gland Neoplasms | 2 | 2018 | 11 | 1.47 | Why? |
| Adenoma | 2 | 2018 | 215 | 1.19 | Why? |
| Exanthema | 3 | 2020 | 1097 | 1.18 | Why? |
| Psoriasis | 13 | 2020 | 1739 | 1.02 | Why? |
| Skin Neoplasms | 6 | 2019 | 1679 | 1.01 | Why? |
| Acantholysis | 2 | 2020 | 18 | 0.97 | Why? |
| Ichthyosis | 2 | 2020 | 35 | 0.96 | Why? |
| Proto-Oncogene Proteins c-fos | 2 | 2019 | 50 | 0.95 | Why? |
| Chickenpox | 2 | 2020 | 194 | 0.79 | Why? |
| Livedo Reticularis | 1 | 2020 | 90 | 0.79 | Why? |
| Hamartoma | 1 | 2019 | 21 | 0.78 | Why? |
| Nevus | 1 | 2019 | 42 | 0.78 | Why? |
| Tuberous Sclerosis | 1 | 2019 | 63 | 0.77 | Why? |
| Mammary Analogue Secretory Carcinoma | 1 | 2018 | 1 | 0.75 | Why? |
| GATA3 Transcription Factor | 1 | 2018 | 16 | 0.74 | Why? |
| Granuloma Annulare | 1 | 2018 | 19 | 0.74 | Why? |
| Hemangioma | 1 | 2019 | 62 | 0.72 | Why? |
| Pemetrexed | 1 | 2017 | 32 | 0.71 | Why? |
| Cysts | 1 | 2019 | 94 | 0.70 | Why? |
| Scalp Dermatoses | 1 | 2018 | 59 | 0.69 | Why? |
| Hemangiosarcoma | 2 | 2018 | 24 | 0.69 | Why? |
| Pleural Neoplasms | 1 | 2017 | 71 | 0.69 | Why? |
| Biomarkers, Tumor | 5 | 2019 | 1314 | 0.68 | Why? |
| Mesothelioma | 1 | 2017 | 76 | 0.67 | Why? |
| Acromegaly | 1 | 2018 | 79 | 0.67 | Why? |
| Xanthomatosis | 1 | 2016 | 11 | 0.66 | Why? |
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2018 | 88 | 0.65 | Why? |
| Drug Eruptions | 2 | 2020 | 319 | 0.65 | Why? |
| Herpes Simplex | 1 | 2020 | 272 | 0.65 | Why? |
| Skin Diseases, Vascular | 1 | 2017 | 69 | 0.64 | Why? |
| Lyme Disease | 1 | 2018 | 102 | 0.64 | Why? |
| Neoplasm Proteins | 2 | 2019 | 501 | 0.63 | Why? |
| Pituitary Neoplasms | 1 | 2018 | 130 | 0.63 | Why? |
| Carcinoma | 1 | 2018 | 256 | 0.58 | Why? |
| Herpes Zoster | 1 | 2020 | 331 | 0.56 | Why? |
| Urticaria | 1 | 2020 | 472 | 0.53 | Why? |
| Dermatologic Agents | 6 | 2018 | 489 | 0.50 | Why? |
| Adenocarcinoma | 1 | 2018 | 651 | 0.43 | Why? |
| Vasculitis | 1 | 2017 | 691 | 0.42 | Why? |
| Emollients | 1 | 2010 | 108 | 0.40 | Why? |
| Diagnosis, Differential | 8 | 2019 | 7220 | 0.38 | Why? |
| Cosmetics | 1 | 2010 | 100 | 0.38 | Why? |
| Breast Neoplasms | 3 | 2019 | 3633 | 0.37 | Why? |
| Foot | 2 | 2020 | 195 | 0.35 | Why? |
| Arthritis, Psoriatic | 3 | 2019 | 625 | 0.35 | Why? |
| Adalimumab | 5 | 2018 | 389 | 0.34 | Why? |
| Etanercept | 3 | 2018 | 162 | 0.34 | Why? |
| Dermatitis, Allergic Contact | 1 | 2010 | 185 | 0.33 | Why? |
| Skin Diseases | 2 | 2020 | 2509 | 0.31 | Why? |
| Head and Neck Neoplasms | 1 | 2018 | 1568 | 0.30 | Why? |
| Tumor Necrosis Factor-alpha | 4 | 2019 | 2483 | 0.28 | Why? |
| Skin Diseases, Viral | 2 | 2020 | 436 | 0.27 | Why? |
| Biological Products | 4 | 2019 | 2331 | 0.25 | Why? |
| Emergencies | 1 | 2017 | 4095 | 0.23 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.23 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.21 | Why? |
| Cecropia Plant | 1 | 2019 | 1 | 0.21 | Why? |
| 12E7 Antigen | 1 | 2019 | 20 | 0.20 | Why? |
| Dermis | 1 | 2019 | 35 | 0.20 | Why? |
| Neurilemmoma | 1 | 2019 | 17 | 0.19 | Why? |
| Middle Aged | 29 | 2021 | 270681 | 0.19 | Why? |
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2018 | 2 | 0.19 | Why? |
| Carcinoma, Skin Appendage | 1 | 2018 | 4 | 0.19 | Why? |
| Warts | 1 | 2019 | 59 | 0.19 | Why? |
| Ustekinumab | 2 | 2018 | 216 | 0.19 | Why? |
| Sebaceous Glands | 1 | 2018 | 9 | 0.19 | Why? |
| Fibroma | 1 | 2018 | 17 | 0.19 | Why? |
| Pharmacogenomic Variants | 1 | 2019 | 112 | 0.19 | Why? |
| Antibodies, Antinuclear | 2 | 2017 | 234 | 0.18 | Why? |
| Tuberculin Test | 1 | 2019 | 141 | 0.18 | Why? |
| Darier Disease | 1 | 2017 | 4 | 0.18 | Why? |
| CD3 Complex | 1 | 2019 | 237 | 0.18 | Why? |
| Oncogene Proteins, Fusion | 1 | 2018 | 52 | 0.18 | Why? |
| Skin | 2 | 2020 | 2096 | 0.17 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.17 | Why? |
| Remission, Spontaneous | 1 | 2018 | 186 | 0.17 | Why? |
| Collagen | 1 | 2019 | 222 | 0.17 | Why? |
| Acitretin | 2 | 2017 | 23 | 0.17 | Why? |
| Soft Tissue Neoplasms | 1 | 2019 | 131 | 0.17 | Why? |
| Humans | 44 | 2021 | 930598 | 0.17 | Why? |
| Female | 31 | 2021 | 380317 | 0.16 | Why? |
| Infliximab | 2 | 2018 | 502 | 0.16 | Why? |
| Histones | 1 | 2018 | 371 | 0.15 | Why? |
| Substance Withdrawal Syndrome | 1 | 2017 | 137 | 0.15 | Why? |
| Hand Injuries | 1 | 2017 | 110 | 0.15 | Why? |
| Aged, 80 and over | 8 | 2020 | 88759 | 0.14 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.14 | Why? |
| Necrosis | 1 | 2017 | 532 | 0.14 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.13 | Why? |
| Scalp | 1 | 2014 | 82 | 0.13 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 526 | 0.13 | Why? |
| Male | 24 | 2020 | 367725 | 0.13 | Why? |
| Aged | 15 | 2020 | 215776 | 0.12 | Why? |
| Immunohistochemistry | 2 | 2018 | 2275 | 0.12 | Why? |
| Biopsy | 1 | 2020 | 2811 | 0.11 | Why? |
| Yoga | 1 | 2014 | 189 | 0.11 | Why? |
| Registries | 4 | 2020 | 12327 | 0.11 | Why? |
| Radiodermatitis | 1 | 2010 | 29 | 0.10 | Why? |
| Autoimmunity | 1 | 2017 | 841 | 0.10 | Why? |
| Polymorphism, Genetic | 1 | 2017 | 1074 | 0.10 | Why? |
| Patch Tests | 1 | 2010 | 114 | 0.10 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.09 | Why? |
| Prospective Studies | 8 | 2020 | 43301 | 0.09 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.09 | Why? |
| Antigens, Nuclear | 2 | 2017 | 32 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Adult | 16 | 2020 | 244371 | 0.08 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2018 | 1380 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.08 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.08 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Antirheumatic Agents | 2 | 2017 | 3023 | 0.07 | Why? |
| Spain | 5 | 2020 | 15545 | 0.07 | Why? |
| Allergens | 1 | 2010 | 728 | 0.07 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Tuberculosis | 1 | 2019 | 2895 | 0.06 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.06 | Why? |
| Epigenesis, Genetic | 2 | 2018 | 711 | 0.06 | Why? |
| Dermatology | 1 | 2017 | 1999 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2019 | 9 | 0.05 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2019 | 29 | 0.05 | Why? |
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 55 | 0.05 | Why? |
| Hemangioendothelioma, Epithelioid | 1 | 2018 | 4 | 0.05 | Why? |
| Perilipin-2 | 1 | 2018 | 7 | 0.05 | Why? |
| Pharmacogenomic Testing | 1 | 2019 | 115 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.05 | Why? |
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2017 | 16 | 0.04 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 229 | 0.04 | Why? |
| Methylation | 1 | 2018 | 332 | 0.04 | Why? |
| Nails, Malformed | 1 | 2017 | 12 | 0.04 | Why? |
| Isotretinoin | 1 | 2017 | 58 | 0.04 | Why? |
| Tretinoin | 1 | 2017 | 99 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Drug Resistance | 1 | 2019 | 395 | 0.04 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.04 | Why? |
| Pharmacogenetics | 1 | 2017 | 222 | 0.04 | Why? |
| DNA-Binding Proteins | 1 | 2019 | 469 | 0.04 | Why? |
| Pain Measurement | 1 | 2019 | 533 | 0.04 | Why? |
| Sarcoma | 1 | 2019 | 290 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.04 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 502 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2019 | 3607 | 0.04 | Why? |
| Dermatologists | 1 | 2020 | 435 | 0.04 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.03 | Why? |
| Terminology as Topic | 1 | 2020 | 546 | 0.03 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.03 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.03 | Why? |
| Keratolytic Agents | 1 | 2012 | 16 | 0.03 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.03 | Why? |
| Adrenal Cortex Hormones | 1 | 2010 | 6537 | 0.03 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 694 | 0.03 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.03 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.03 | Why? |
| DNA | 1 | 2017 | 778 | 0.03 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.03 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.02 | Why? |
| Age Distribution | 1 | 2018 | 3567 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2019 | 2165 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.02 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.02 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2012 | 7268 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
Llamas-Velasco's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(188)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(110)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_